|
|
 |
|
 |
The Function of ETB Receptors* in Pulmonary Arterial Hypertension (PAH) |
|
|
|
In PAH, ETB Receptors Located on the Smooth Muscle Cell Become Pathogenic Mediators* |
|
|
|
*Statements are based on observations reported from in vitro or animal trials.
The clinical significance in humans is unknown. |
|
|
|
|
|
Blockade of Endothelin Receptors May Provide Benefits*7 |
|
|
|
*Statements are based on observations reported from in vitro or animal trials.
The clinical significance in humans is unknown. |
|
REFERENCES |
|
1. |
Kim NH, Rubin LJ. Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension. J Cardiovasc Pharmacol Ther. 2002;7:9–19. |
|
2. |
Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol. 2001;41:851–876. |
|
3. |
Goraca A. New views on the role of endothelin. Endocr Regul. 2002;36:161–167. |
|
4. |
Davie N, Haleen SJ, Upton PD, et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care
Med. 2002;165:398–405. |
|
5. |
Muller DN, Mervaala EM, Schmidt F, et al. Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. Hypertension. 2000;36:282–290. |
|
6. |
Miyauchi T, Masaki T. Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol. 1999;61:391–415. |
|
7. |
Rich S, McLaughlin VV. Pulmonary hypertension. In: Libby P, Bonow RO, Mann DL, Zipes DE. Braunwald's Heart Disease. 2 vols. 8th ed. Philadelphia, PA: Saunders Elsevier; 2008:1883–1914. |
|
|
|
|
|
|
|
 |
